News | 09 January 2013
A majority of surveyed pharmaceutical companies outsource at least part of their regulatory affairs budget. This is up 5% from 2010, demonstrating that fewer drug companies are trying to keep such activities entirely in-house than before, according to ...
Click on the link to read the full article at PharmiWeb.com (press release)
(This link will open in a new window)